PMID- 18790702
OWN - NLM
STAT- MEDLINE
DCOM- 20090415
LR  - 20131121
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 55
IP  - 8
DP  - 2008 Dec
TI  - Neonatal administration of N-omega-nitro-L-arginine induces permanent decrease in 
      NO levels and hyperresponsiveness to locomotor activity by D-amphetamine in 
      postpubertal rats.
PG  - 1313-20
LID - 10.1016/j.neuropharm.2008.08.019 [doi]
AB  - Nitric oxide (NO) is associated with dopamine (DA) release. Previously, we 
      demonstrated that rats treated with a non-selective nitric oxide synthase 
      inhibitor, N-omega-nitro-L-arginine (L-NNA) at postnatal days 4-6 (PD4-6) show 
      increased locomotion and disrupt neuronal cytoarchitecture after puberty (PD60). 
      Here, we investigate whether the modulation of NO production in rats at PD4-6 
      causes long term changes of NO system, its impact on DA innervation, and 
      schizophrenia-like behaviors. NO levels were measured in seven brain areas at 
      PD35, PD60, PD90, and PD120. Autoradiographic studies explored the effect of 
      l-NNA on the expression of D1 and D2 receptors in the caudate-putamen (CPu) and 
      nucleus accumbens (NAcc) at PD60. Locomotor activity was assessed at PD60 using 
      the non-selective DA agonists, amphetamine and apomorphine, and the selective DA 
      receptor agonist [D2, quinpirole; D3, 7-hydroxy-N,N-di-n-propylaminotetralin 
      ((+/-)-7-OH-DPAT)]. L-NNA treatment produced decreases in NO levels in the 
      frontal cortex, striatum, brainstem and cerebellum, while in the occipital cortex 
      changes were observed at PD120. Hippocampus and temporoparietal cortex showed 
      differential levels of NO. Receptor autoradiography revealed increases in D1 
      receptor levels in the NAcc (shell), while decreases in D2 receptor binding were 
      observed in the CPu and NAcc (core). Amphetamine and quinpirole treatments 
      resulted in increases in locomotion. In contrast, treatment with 7-OH-DPAT 
      produced hypolocomotion at low doses, while increased locomotion was seen at the 
      highest dose. These results show that modulation of NO levels early postnatally 
      (PD4-6) produces long term alteration in NO levels, with possible consequences on 
      DA transmission, and related behaviors relevant to schizophrenia.
FAU - Morales-Medina, Julio Cesar
AU  - Morales-Medina JC
AD  - Laboratorio de Neuropsiquiatria, Instituto de Fisiologia, Universidad Autonoma de 
      Puebla, 14 Sur 6301, Col. San Manuel, CP 72570 Puebla, Mexico.
FAU - Mejorada, Alejandro
AU  - Mejorada A
FAU - Romero-Curiel, Alejandra
AU  - Romero-Curiel A
FAU - Aguilar-Alonso, Patricia
AU  - Aguilar-Alonso P
FAU - Leon-Chavez, Bertha Alicia
AU  - Leon-Chavez BA
FAU - Gamboa, Citlalli
AU  - Gamboa C
FAU - Quirion, Remi
AU  - Quirion R
FAU - Flores, Gonzalo
AU  - Flores G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080826
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dopamine Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Receptors, Dopamine D2)
RN  - 2149-70-4 (Nitroarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - TZ47U051FI (Dextroamphetamine)
SB  - IM
MH  - Age Factors
MH  - Analysis of Variance
MH  - Animals
MH  - Animals, Newborn
MH  - Autoradiography
MH  - Brain/drug effects/metabolism
MH  - Central Nervous System Stimulants/*pharmacology
MH  - Dextroamphetamine/*pharmacology
MH  - Dopamine Agents/pharmacology
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Motor Activity/*drug effects
MH  - Nitric Oxide/*metabolism
MH  - Nitroarginine/*pharmacology
MH  - Pregnancy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/metabolism
MH  - Receptors, Dopamine D2/metabolism
MH  - Time Factors
EDAT- 2008/09/16 09:00
MHDA- 2009/04/16 09:00
CRDT- 2008/09/16 09:00
PHST- 2008/01/25 00:00 [received]
PHST- 2008/06/26 00:00 [revised]
PHST- 2008/08/14 00:00 [accepted]
PHST- 2008/09/16 09:00 [pubmed]
PHST- 2009/04/16 09:00 [medline]
PHST- 2008/09/16 09:00 [entrez]
AID - S0028-3908(08)00377-8 [pii]
AID - 10.1016/j.neuropharm.2008.08.019 [doi]
PST - ppublish
SO  - Neuropharmacology. 2008 Dec;55(8):1313-20. doi: 10.1016/j.neuropharm.2008.08.019. 
      Epub 2008 Aug 26.